AI Biomed PredictionsMNPR – Mid-2026 NDA filing could reignite Monopar’s rare-disease rally ScanScor Admin / June 9, 2026
AI Biomed PredictionsUNCY – UNCY Faces Make-or-Break FDA Catalyst With Approval Upside ScanScor Admin / May 31, 2026
AI Biomed PredictionsIMRX – ASCO Data Will Decide Whether IMRX Earns Its Re-Rating ScanScor Admin / May 30, 2026
AI Biomed PredictionsCRDF – ASCO Data Could Decide Cardiff Oncology’s Next Sharp Repricing ScanScor Admin / May 28, 2026
AI Biomed PredictionsLXEO – Lexeo Nears Pivotal FDA Decision That Could Reprice Shares ScanScor Admin / May 20, 2026
AI Biomed PredictionsABEO – ZEVASKYN launch traction could force ABEO’s next sharp rerating ScanScor Admin / May 20, 2026
AI Biomed PredictionsNGNE – Mid-2026 Rett data could reignite Neurogene’s breakout case ScanScor Admin / May 12, 2026
AI Biomed PredictionsABEO – ZEVASKYN launch proof could ignite Abeona’s next sharp rerating ScanScor Admin / May 10, 2026
AI Biomed PredictionsTNYA – ASGCT TN-401 data could decide Tenaya’s next sharp rerating ScanScor Admin / May 2, 2026
AI Biomed PredictionsELTX – ELTX nears binary pancreatic cancer readout with breakout potential ScanScor Admin / April 21, 2026
